Heike Brötz-Oesterhelt

Heike Brötz-Oesterhelt (born 12 May 1968, in Neuwied) is a German microbiologist. She is a full professor and holds the Chair of the Department for Microbial Bioactive Compounds at the Interfaculty Institute for Microbiology and Infection Medicine, University of Tübingen, Germany.[1]

Heike Brötz-Oesterhelt
Born (1968-05-12) May 12, 1968
Neuwied)
CitizenshipGermany
Occupationmicrobiologist
EmployerUniversity of Tübingen

Life

Brötz-Oesterhelt studied biology at the University of Bonn, Germany. During her PhD (1993 – 1997) at the Medical Department of the University of Bonn, she specialized in microbiology and antibiotic research. After gaining her doctorate, she went into industry and worked as a senior scientist and project manager at the Anti-Infective Research Department of Bayer HealthCare at the Pharma Research Centre, Wuppertal, Germany. She became Biological Coordinator of Exploratory Antibacterial Research at Bayer HealthCare in 2004. She left Bayer in 2006 and co-founded the company AiCuris, Wuppertal, a biotech spin-off of the antibacterial and antiviral research department of Bayer. From 2006 – 2009, she was Head of Antibacterial Research and from 2009 – 2010 Head of Bacteriology at AiCuris. She returned to the academic world as Professor for Pharmaceutical Biology at the University of Düsseldorf, Germany in 2010.[2] She has been a Full Professor at the University of Tübingen and a member of the Interfaculty Institute for Microbiology and Infection Medicine since 2014.[3]

Research

Brötz-Oesterhelt's research focuses on discovering and characterizing new antibiotics. She studies molecular mechanisms of antibiotic action and the workings of new antibiotic targets. Her department is dedicated to finding new mechanisms for killing multi-drug resistant bacterial pathogens. She discovered, for example, that nisin and other lantibiotics use the cell wall precursor lipid II as a docking molecule to form pores in the bacterial membrane and that acyldepsipeptide (ADEP) antibiotics deregulate the bacterial Clp protease.[4]

Awards
  • Clinical Research and Development Publication Award, Pfizer Inc., 2006
  • Research Innovation Prize from Bayer HealthCare AG, 2004
  • PhD Award from the German Association for General and Applied Microbiology VAAM, 1998

Publications
  • Zipperer, A., Konnerth, M.C., Laux. C., Berscheid, A., Janek, D., Weidenmaier, C., Burian, M., Schilling, N.A., Slavetinsky, C., Marschal, M., Willmann, M., Kalbacher, H., Schittek, B., Brötz-Oesterhelt, H., Grond, S., Peschel, A., Krismer, B. 2016. “Human commensals producing a novel antibiotic impair pathogen colonization.” Nature 535 (7613): 511-6 (2016).[5]
  • Gersch, M., Famulla, K., Dahmen, M., Göbl, C., Malik, I., Richter, K., Korotkoc, V.S., Sass, P., Rübsamen-Schaeff, H., Madl, T, Brötz-Oesterhelt, H., and Sieber, p. 2015. “AAA+ chaperones and acyldepsipeptides activate ClpP via conformational control.” Nature Communications 6:6320 (2015).[6]
  • Sass, P., M. Josten, K. Famulla, G. Schiffer, H.-G. Sahl, L. Hamoen and H. Brötz-Oesterhelt. “Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ.” PNAS 108, 17474-17479 (2011).[7]
  • Brötz-Oesterhelt, H., D. Beyer, H.-P. Kroll, R. Endermann, C. Ladel, W. Schroeder, B. Hinzen, S. Raddatz, H. Paulsen, K. Henninger, J. E. Bandow, H.-G. Sahl and H. Labischinski. “Dysregulation of bacterial proteolytic machinery by a new class of antibiotics.” Nature Medicine. 11, 1082-1087 (2005).[8]
  • Brötz, H., M. Josten, I. Wiedemann, U. Schneider, G. Bierbaum and H.-G. Sahl: “Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics.” Molecular Microbiology 30, 317-328 (1998).[9]
gollark: However, good luck getting GPUs for that.
gollark: EleutherAI are releasing their 20-billion-parameter model in about a week.
gollark: It's proprietary.
gollark: You can't run it.
gollark: How else would it do it? All is to large language models.

References
  1. "Staff - Interfaculty Institute of Microbiology and Infection Medicine Tübingen - University Tübingen". Uni-tuebingen.de. Retrieved 3 January 2018.
  2. "Universität Düsseldorf: Prof. Dr. Heike Brötz-Oesterhelt". Biostruct.uni-duesseldorf.de. Retrieved 3 January 2018.
  3. "Team Brötz-Oesterhelt - Interfaculty Institute of Microbiology and Infection Medicine Tübingen - - University Tübingen". www.uni-tuebingen.de.
  4. "Heike Brötz-Oesterhelt - searching for novel antibiotics in bacteria". Gesundheitsindustrie-bw.de. Retrieved 3 January 2018.
  5. Zipperer, Alexander; Konnerth, Martin C.; Laux, Claudia; Berscheid, Anne; Janek, Daniela; Weidenmaier, Christopher; Burian, Marc; Schilling, Nadine A.; Slavetinsky, Christoph; Marschal, Matthias; Willmann, Matthias; Kalbacher, Hubert; Schittek, Birgit; Brötz-Oesterhelt, Heike; Grond, Stephanie; Peschel, Andreas; Krismer, Bernhard (28 July 2016). "Human commensals producing a novel antibiotic impair pathogen colonization". Nature. 535 (7613): 511–516. doi:10.1038/nature18634. PMID 27466123.
  6. Gersch, Malte; Famulla, Kirsten; Dahmen, Maria; Göbl, Christoph; Malik, Imran; Richter, Klaus; Korotkov, Vadim S.; Sass, Peter; Rübsamen-Schaeff, Helga; Madl, Tobias; Brötz-Oesterhelt, Heike; Sieber, Stephan A. (19 February 2015). "AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control". Nat Commun. 6: 6320. doi:10.1038/ncomms7320. PMID 25695750.
  7. Sass, Peter; Josten, Michaele; Famulla, Kirsten; Schiffer, Guido; Sahl, Hans-Georg; Hamoen, Leendert; Brötz-Oesterhelt, Heike (18 October 2011). "Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ". Proc. Natl. Acad. Sci. U.S.A. 108 (42): 17474–17479. doi:10.1073/pnas.1110385108. PMC 3198362. PMID 21969594.
  8. Brötz-Oesterhelt, Heike; Beyer, Dieter; Kroll, Hein-Peter; Endermann, Rainer; Ladel, Christoph; Schroeder, Werner; Hinzen, Berthold; Raddatz, Siegfried; Paulsen, Holger; Henninger, Kerstin; Bandow, Julia E.; Sahl, Hans-Georg; Labischinski, Harald (1 October 2005). "Dysregulation of bacterial proteolytic machinery by a new class of antibiotics". Nat. Med. 11 (10): 1082–1087. doi:10.1038/nm1306. PMID 16200071.
  9. Brötz, H.; Josten, M.; Wiedemann, I.; Schneider, U.; Götz, F.; Bierbaum, G.; Sahl, H. G. (1 October 1998). "Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics". Mol. Microbiol. 30 (2): 317–327. doi:10.1046/j.1365-2958.1998.01065.x. PMID 9791177.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.